JP2018203747A5 - - Google Patents

Download PDF

Info

Publication number
JP2018203747A5
JP2018203747A5 JP2018150978A JP2018150978A JP2018203747A5 JP 2018203747 A5 JP2018203747 A5 JP 2018203747A5 JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018203747 A5 JP2018203747 A5 JP 2018203747A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
cholesterol
diabetes
use according
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018150978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018203747A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018203747A publication Critical patent/JP2018203747A/ja
Publication of JP2018203747A5 publication Critical patent/JP2018203747A5/ja
Priority to JP2021103893A priority Critical patent/JP2021155436A/ja
Priority to JP2023146755A priority patent/JP2023178518A/ja
Pending legal-status Critical Current

Links

JP2018150978A 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法 Pending JP2018203747A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021103893A JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
US61/624,087 2012-04-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015505963A Division JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103893A Division JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法

Publications (2)

Publication Number Publication Date
JP2018203747A JP2018203747A (ja) 2018-12-27
JP2018203747A5 true JP2018203747A5 (enExample) 2019-05-16

Family

ID=49328287

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Country Status (8)

Country Link
US (4) US10195227B2 (enExample)
EP (2) EP2836221B1 (enExample)
JP (4) JP6491089B2 (enExample)
CN (2) CN104244956B (enExample)
CA (1) CA2870316C (enExample)
ES (1) ES2959119T3 (enExample)
MX (2) MX371073B (enExample)
WO (1) WO2013155485A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836221B1 (en) * 2012-04-13 2023-07-05 L&F Research LLC Method of using cyclodextrin
CN105611909B (zh) 2013-03-12 2020-09-15 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
EP3307278A4 (en) 2015-06-10 2018-06-13 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
CN112996562A (zh) 2018-10-29 2021-06-18 赛克洛治疗股份有限公司 治疗阿尔茨海默病的方法
US11279774B2 (en) 2019-01-03 2022-03-22 Underdog Pharmaceuticals, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
PH12021552553A1 (en) * 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
EP4203974A4 (en) * 2020-08-27 2024-08-07 Beren Therapeutics P.B.C. METHOD FOR TREATING CARDIOVASCULAR DISEASES WITH CYCLODEXTRINS
WO2022047241A1 (en) * 2020-08-27 2022-03-03 Beren Therapeutics P.B.C. Methods for the treatment of cholesterol crystal embolization with cyclodextrins
CN116635007A (zh) * 2020-08-27 2023-08-22 贝伦治疗公益公司 用环糊精预防胆固醇结晶栓塞的方法
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
US20220260597A1 (en) * 2021-02-18 2022-08-18 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
CN116322710A (zh) * 2021-09-01 2023-06-23 株式会社雷纳图斯 包括γ-环糊精聚合物的药物组合物以及其用途
KR20240160120A (ko) 2022-02-18 2024-11-08 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린의 조성물 및 이의 정제 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6756504B2 (en) 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
WO2004016101A2 (en) 2002-08-19 2004-02-26 Art Jen Complexus, Inc. Compositions comprising dietary fat complexer and methods for their use
JP2004323443A (ja) 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
JP5069130B2 (ja) 2005-01-27 2012-11-07 エリモス・ファーマスーティカルズ・エルエルシー Ｎｄｇａ化合物を包含するカテコールブタンの送達のための経口用製剤
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
UA95310C2 (ru) * 2006-10-20 2011-07-25 Айкос Корпорейшен Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
CA2740003A1 (en) * 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrone analogs for therapeutic treatment
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
EP2352502A4 (en) 2008-11-06 2012-12-26 Univ Miami LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE
US20110314423A1 (en) 2009-03-12 2011-12-22 Panasonic Corporation Image display device and image display method
WO2011043630A2 (ko) 2009-10-08 2011-04-14 (주)송호바이오메드 고 수용성 ２-하이드록시프로필-베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
WO2011057172A1 (en) 2009-11-06 2011-05-12 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) * 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
US10052345B2 (en) * 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
EP2836221B1 (en) * 2012-04-13 2023-07-05 L&F Research LLC Method of using cyclodextrin

Similar Documents

Publication Publication Date Title
US20230338412A1 (en) Method of using cyclodextrin
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
Pisciotta et al. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
US20050032761A1 (en) Lipid profile modulation
CA3101274A1 (en) Use of neutrophil elastase inhibitors in liver disease
CN105008394A (zh) 治疗结肠直肠癌的方法
US20250262190A1 (en) Use of lat1 inhibitors to treat obesity
KR102218498B1 (ko) Fxr 작용제들의 조합물
KR20190044667A (ko) Fxr 작용제의 신규 요법
US10758551B2 (en) Methods and compositions for treating pancreatitis
Zhou et al. Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells
HK40032085A (en) Method of using cyclodextrin
WO2011153209A2 (en) Cd36 inhibition to control obesity and insulin sensitivity
US20080020982A1 (en) Methods and compositions for treatment of atherosclerosis
Liu et al. Erythropoietin alleviate obstructive renal fibrosis by regulating immunity and inflammation through miR-21-5p/SPRY1/ERK1/2/NF-κB pathway inhibition
Zhang Molecular mechanisms and novel therapeutic targets of diabetic kidney disease
WO2018027149A1 (en) Methods of treating alport syndrome
WO2025096597A1 (en) Compositions including inhibitors of pten expression or activity to prevent or treat type 2 diabetes
WO2026082873A1 (en) Use of caspase-1 inhibitors for treating ineffective erythropoiesis in patients suffering from sickle cell disease